Logo

Ono Pharmaceutical and InveniAI Collaborate to Identify Novel Therapeutic Targets Using Artificial Intelligence (AI) and Machine Learning (ML)

Share this

Ono Pharmaceutical and InveniAI Collaborate to Identify Novel Therapeutic Targets Using Artificial Intelligence (AI) and Machine Learning (ML)

Shots:

  • Ono and InveniAI have signed a research collaboration agreement for the identification of novel therapeutic targets using the latter’s artificial intelligence (AI) and machine learning (ML)
  • Under the collaboration, InveniAI will utilize its AI technologies, AlphaMeld & ChatAlphaMeld, to identify new therapeutic targets for various diseases specified by Ono. Moreover, through AI & ML algorithms along with Generative AI tools, the company will propose drug discovery hypotheses for optimization
  • Ono will commence the confirmation studies to validate the hypotheses and will hold back the global exclusive development and commercialization rights of these identified drug candidates

Ref: Ono Pharmaceutical | Image: Ono Pharmaceutical 

Related News:- Numab Therapeutics Reports the First Patient Dosing in P-I Multiple Ascending Dose Study of NM26 for Moderate to Severe Atopic Dermatitis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions